Safety Aspects of the Use of Quercetin as a Dietary Supplement

被引:509
作者
Andres, Susanne [2 ]
Pevny, Sophie [2 ]
Ziegenhagen, Rainer [1 ]
Bakhiya, Nadiya [1 ]
Schaefer, Bernd [1 ]
Hirsch-Ernst, Karen Ildico [1 ]
Lampen, Alfonso [1 ]
机构
[1] German Fed Inst Risk Assessment BfR, Dept Food Safety, Berlin, Germany
[2] German Fed Inst Risk Assessment BfR, Dept Food Safety, Berlin, Germany
关键词
adverse effects; drug interaction; nephrotoxicity; quercetin; tumor promotion; IN-VITRO; FLAVONOID QUERCETIN; BLOOD-PRESSURE; P-GLYCOPROTEIN; TOPOISOMERASE-I; CYP3A ACTIVITY; HEART-DISEASE; DOUBLE-BLIND; RISK-FACTORS; PHARMACOKINETICS;
D O I
10.1002/mnfr.201700447
中图分类号
TS2 [食品工业];
学科分类号
100403 [营养与食品卫生学];
摘要
The flavonoid quercetin is frequently found in low amounts as a secondary plant metabolite in fruits and vegetables. Isolated quercetin is also marketed as a dietary supplement, mostly as the free quercetin aglycone, and frequently in daily doses of up to 1000 mg d(-1) exceeding usual dietary intake levels. The present review is dedicated to safety aspects of isolated quercetin used as single compound in dietary supplements. Among the numerous published human intervention studies, adverse effects following supplemental quercetin intake have been rarely reported and any such effects were mild in nature. Published adequate scientific data for safety assessment in regard to the long-term use (> 12 weeks) of high supplemental quercetin doses (>= 1000 mg) are currently not available. Based on animal studies involving oral quercetin application some possible critical safety aspects could be identified such as the potential of quercetin to enhance nephrotoxic effects in the predamaged kidney or to promote tumor development especially in estrogen-dependent cancer. Furthermore, animal and human studies with single time or short-term supplemental quercetin application revealed interactions between quercetin and certain drugs leading to altered drug bioavailability. Based on these results, some potential risk groups are discussed in the present review.
引用
收藏
页数:15
相关论文
共 179 条
[1]
Quercetin attenuates di-(2-ethylhexyl) phthalate-induced testicular toxicity in adult rats [J].
Abd-Ellah, M. F. ;
Aly, H. A. A. ;
Mokhlis, H. A. M. ;
Abdel-Aziz, A. H. .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2016, 35 (03) :232-243
[2]
Aeschbacher H U, 1982, Nutr Cancer, V4, P90, DOI 10.1080/01635588209513744
[3]
AFSSA (Agence Francaise de Securite Sanitaire des Aliments), 2008, AVIS AG FRANC SEC SA, P41
[4]
Agostoni C, 2011, EFSA J, V9
[5]
[Anonymous], 1999, IARC Monogr Eval Carcinog Risks Hum, V73, P497
[6]
[Anonymous], 2010, AG RESP LETT GRAS NO
[7]
Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models [J].
Babu, P. Ravindra ;
Babu, K. Naveen ;
Peter, P. L. Haroled ;
Rajesh, K. ;
Babu, P. Jawahar .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (06) :873-879
[8]
Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan [J].
Bakheet, Saleh A. .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2011, 2011
[9]
Quercetin changes purinergic enzyme activities and oxidative profile in platelets of rats with hypothyroidism [J].
Baldissarelli, Jucimara ;
Santi, Adriana ;
Schmatz, Roberta ;
Zanini, Daniela ;
Cardoso, Andreia M. ;
Abadalla, Fatima H. ;
Thome, Gustavo R. ;
Murussi, Camila ;
Polachini, Carla R. N. ;
Delenogare, Diessica P. ;
Loro, Vania L. ;
Morsch, Vera M. ;
Schetinger, Maria R. C. .
BIOMEDICINE & PHARMACOTHERAPY, 2016, 84 :1849-1857
[10]
Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein [J].
Bansal, Tripta ;
Awasthi, Anshumali ;
Jaggi, Manu ;
Khar, Roop K. ;
Talegaonkar, Sushama .
LIFE SCIENCES, 2008, 83 (7-8) :250-259